Alpha Crest Capital Management LLC Denali Therapeutics Inc. Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $180,075 - $267,167	6,934 Added 52.14%	20,234 $621,000
Q2 2022 Aug 11, 2022	SELL	$20.88 - $35.19 $290,232 - $489,140	-13,900 Reduced 51.1%	13,300 $391,000
Q1 2022 May 12, 2022	BUY	$29.0 - $47.27 $504,281 - $821,978	17,389 Added 177.24%	27,200 $875,000
Q4 2021 Feb 09, 2022	BUY	$42.59 - $55.02 $145,274 - $187,673	3,411 Added 53.3%	9,811 $438,000
Q3 2021 Nov 10, 2021	BUY	$48.48 - $78.23 $310,272 - $500,672	6,400 New	6,400 $323,000
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $674,020 - $1.05 Million	-13,400 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$53.8 - $81.53 $720,920 - $1.09 Million	13,400 New	13,400 $765,000
Q3 2020 Nov 12, 2020	SELL	$23.13 - $38.84 $390,897 - $656,396	-16,900 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$16.01 - $28.82 $270,569 - $487,058	16,900 New	16,900 $409,000
Q4 2019 Feb 12, 2020	SELL	$14.4 - $19.99 $203,040 - $281,859	-14,100 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$15.32 - $21.92 $216,012 - $309,072	14,100 New	14,100 $216,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.